Atrial Fibrillation Clinical Trials

Find Atrial Fibrillation Clinical Trials Near You

Development of an Atrial Fibrillation Prediction Model Using Polygenic Risk Score: A Prospective Cohort Study

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Genetic, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to learn whether a genetic risk score can help identify undiagnosed atrial fibrillation (AF) in adults who may have it. AF is an irregular heartbeat that raises the risk of stroke if not treated early. The main questions it aims to answer are: Can a polygenic risk score (PRS) - a score based on a person's genes - identify who is more likely to have AF? Does combining PRS with a person's medical history predict AF better than using medical history alone? Participants will: Wear a continuous ECG patch for 7 days to record heart rhythm Give a blood sample for genetic testing to calculate their PRS Use a six-lead handheld ECG device (HATIV® P30, VUNO Inc., Seoul, Republic of Korea) to check their own heart rhythm at home once or twice a week for 1 year Visit the clinic 5 times over 1 year Researchers will use the genetic and clinical information collected to build a scoring system that predicts who is at risk for AF.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 79
Healthy Volunteers: f
View:

• Patients with symptoms suggestive of paroxysmal atrial fibrillation, such as intermittent palpitations or chest discomfort

• Asymptomatic patients aged 60 or older with at least one of the following risk factors for atrial fibrillation: hypertension, diabetes, coronary artery disease, valvular heart disease, cardiomyopathy, sleep apnea, hyperthyroidism, obesity (BMI greater than 30), or chronic alcohol dependence (drinking more than 3 times per week)

Locations
Other Locations
Republic of Korea
The Catholic University of Korea Incheon St. Mary's Hospital
RECRUITING
Incheon
The Catholic University of Korea Eunpyeong St. Mary's Hospital
RECRUITING
Seoul
The Catholic University of Korea Seoul St. Mary's Hospital
RECRUITING
Seoul
The Catholic University of Korea St. Vincent's Hospital
RECRUITING
Suwon
The Catholic University of Korea Uijeongbu St. Mary's Hospital
RECRUITING
Uijeongbu-si
Contact Information
Primary
Young Choi, MD, PhD
superstar@catholic.ac.kr
82-2-1588-1511
Time Frame
Start Date: 2024-11-19
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 800
Treatments
Experimental: AF Risk Group
Participants at risk for atrial fibrillation undergo 7-day continuous ECG patch monitoring and SNP array genotyping at enrollment, followed by 1-year self-monitoring with a six-lead handheld ECG device (HATIV® P30, VUNO Inc.).
Related Therapeutic Areas
Sponsors
Leads: Seoul St. Mary's Hospital

This content was sourced from clinicaltrials.gov